title: Dermatologic uses of omalizumabtitle.
abstract: OBJECTIVE
  Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Omalizumab has been approved for use in asthma, and new reports show promise in a variety of dermatologic diseases. Herein, we review the literature on omalizumab in dermatology and discuss the safety, efficacy and mechanisms of action for this emerging therapy.
  
  
  METHODS
  PubMED, MEDLINE and Embase databases were searched for the period 1 January 1990 to 1 September 2016. Articles sourced were graded according to the Oxford Center for Evidence-Based Medicine Levels of Evidence Grades of Recommendation criteria.
  
  
  RESULTS
  A total of 99 articles met our inclusion criteria. They included reports on the use of omalizumab in chronic spontaneous urticaria, atopic dermatitis, mastocytosis, hyper-IgE syndrome, bullous pemphigoid, Netherton syndrome, urticarial vasculitis, Churg-Strauss syndrome and toxic epidermal necrolysis.
  
  
  CONCLUSIONS
  Omalizumab is effective in a variety of recalcitrant immune-mediated and autoimmune skin disorders. It is a safe and effective treatment for use in chronic idiopathic urticaria (Grade of recommendation: A). Randomized clinical trials with long-term follow-ups are warranted to firmly establish the role of omalizumab in the treatment of dermatologic disease.
authors.affiliation: a Division of Dermatology, Department of Medicine , University of Calgary , Calgary , Alberta , Canada.
authors.forename: Justin C
authors.initials: JC
authors.lastname: Chia
authors.affiliation: a Division of Dermatology, Department of Medicine , University of Calgary , Calgary , Alberta , Canada.
authors.forename: P Régine
authors.initials: PR
authors.lastname: Mydlarski
mesh_terms: D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D002908:Chronic Disease; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000276:immunology; D017408:Guidelines as Topic; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D010391:Pemphigoid, Bullous / Q000188:drug therapy / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D014581:Urticaria / Q000188:drug therapy / Q000276:immunology
chemical_list: D018926:Anti-Allergic Agents; D000911:Antibodies, Monoclonal; D000069444:Omalizumab; D007073:Immunoglobulin E
keywords: Omazliumab; bullous pemphigoid; eczema; urticaria